LivaNova PLC's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 2/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 67.73.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
LivaNova PLC's Score
Industry at a Glance
Industry Ranking
2 / 208
Overall Ranking
29 / 4582
Industry
Healthcare Equipment & Supplies
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
10
analysts
Buy
Current Rating
67.732
Target Price
+8.08%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
LivaNova PLC Highlights
StrengthsRisks
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 22.67% year-on-year.
Fairly Valued
The company’s latest PE is -15.77, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 56.86M shares, decreasing 13.00% quarter-over-quarter.
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
Ticker SymbolLIVN
CompanyLivaNova PLC
CEOMakatsaria (Vladimir A)
Websitehttps://www.livanova.com/
FAQs
What is the current price of LivaNova PLC (LIVN)?
The current price of LivaNova PLC (LIVN) is 62.820.
What is the symbol of LivaNova PLC?
The ticker symbol of LivaNova PLC is LIVN.
What is the 52-week high of LivaNova PLC?
The 52-week high of LivaNova PLC is 65.574.
What is the 52-week low of LivaNova PLC?
The 52-week low of LivaNova PLC is 32.480.
What is the market capitalization of LivaNova PLC?
The market capitalization of LivaNova PLC is 3.43B.
What is the net income of LivaNova PLC?
The net income of LivaNova PLC is 63.23M.
Is LivaNova PLC (LIVN) currently rated as Buy, Hold, or Sell?
According to analysts, LivaNova PLC (LIVN) has an overall rating of Buy, with a price target of 67.732.
What is the Earnings Per Share (EPS TTM) of LivaNova PLC (LIVN)?
The Earnings Per Share (EPS TTM) of LivaNova PLC (LIVN) is -3.983.